Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Moderna Shows 100% Efficacy In Teens

Plus, J&J's Vaccine Filed In Japan, Korea, India Supply Developments

Executive Summary

Moderna's mRNA-1273 vaccine prevented significant illness after two doses in all patients in the TeenCOVE trial, ages 12-18. The company will submit the data to global regulators in June. Meanwhile, J&J has applied for the Japanese approval of its vaccine, Moderna progresses plans in Korea, and India plans to ramp up vaccine supplies.

You may also be interested in...



Does New Study Question Need for Pediatric COVID-19 Vaccines?

A recent study says a cohort of unvaccinated individuals aged under 16 years in Israel showed a nearly two-fold decrease in COVID-19 positivity for each 20 percentage points of individuals vaccinated overall. As Pfizer, Moderna and Bharat Biotech develop pediatric vaccines, should they consider if herd immunity might make such vaccines redundant?

New Options For Japan As More COVID-19 Vaccines Finally Approved

Japan has granted emergency approvals to two more vaccines for COVID-19, both from multinational developers, as it finally expands a so far very limited armory against the pandemic. 

J&J Vaccine: Some CDC Advisors Question Warning’s Strength As Clot Reports Grow, Female Use Drops

Some ACIP members argued woman older than 50 should also be singled out in warning for Johnson & Johnson’s COIVD-19 vaccine and said that people need to be more clearly told they can get alternative vaccines that don’t have this risk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel